Effect of Botulinum Toxin Type A on a Rat Surgical Wound Model by Lee, Byung-Joo et al.
20
INTRODUCTION
The treatment for scar in a tubal structure, such as laryngeal, tra-
cheal and nasal stenosis, remains one of the most difficult prob-
lems in the field of head and neck surgery. Scar formation and
restenosis remain the main causes of failure in the surgical man-
agement of airway stenosis. Several topical or injected drugs (such
as triamcinolone acetonide, 5-fluorouracil and mitomycin-C) have
been widely used to overcome scarring and they achieve some
symptomatic relief, but the final results for scar reduction or res-
olution are not always satisfactory (1-4). Mitomycin-C has both
antineoplastic and antiproliferative properties. Its antineoplastic
activity is similar to that of the alkylating agents, with their abil-
ity to cross-link DNA and inhibit both RNA synthesis and pro-
tein synthesis (5, 6). The antiproliferative action of mitomycin-
C can inhibit the proliferative activity of fibroblasts (7). The canine
vocal folds treated with topical mitomycin-C after microflap exci-
sion showed fewer fibroblasts and less collagen deposition in the
lamina propria with reduced mucosal waves (8).
In the recent years, the use of topical and injected mitomycin-
Objectives. The tension on a wound is one of the important factors that determine the degree of fibrosis and scar forma-
tion. We hypothesized that local botulinum toxin type A (Botox) induced paralysis of the musculature subjacent
to a surgical wound with a skin defect would minimize the repetitive tensile forces on the surgical wound’s edges,
and this will result in a decreased fibroplastic response and fibrosis of the wound.
Methods. This is a prospective randomized experimental study. Two distinct surgical wounds were made to the dorsum
of 15 adult rats, respectively. One of the 2 wounds was injected with Botox, and the other wound was used as a
control, and this was done for all the rats’ wounds. We evaluated the wound size, the degree of fibrosis and inflam-
mation, the blood vessel proliferation, the thickness of the wound and the expression of transforming growth fac-
tor (TGF)-β 1 in the wounds.
Results. There were significant differences of wound size at the 3rd and 4th week between the Botox and control groups
(P<0.05). The Botox group showed less infiltration of inflammatory cells than the control group at the 2nd week
(P<0.05). The Botox group showed a smaller number of fibroblasts and less fibrosis than the control group at the
4th week (P<0.05). The Botox group showed much strong collagen density than the control group at the 8th week
(P<0.05). For the immunohistochemical staining, there was a lower transforming growth factor (TGF)-β 1 expres-
sion in the Botox group than that of the control group at the 4th week (P<0.05).
Conclusion. The wounds of the Botox-treated group showed a larger wound size, less infiltration of inflammatory cells
and less fibrosis, a much greater amount of collagen and a lower expression of TGF-β 1 than did the control group.
Botox might be used to decrease the fibrosis of a surgical wound without damaging the epithelial growth in situa-
tions for which decreased fibrosis is necessary, such as for treating laryngeal, tracheal and nasal stenosis.
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Original ArticleC has been proposed as a treatment option for laryngeal steno-
sis, but there are still insufficient experimental and clinical stud-
ies on its short and long-term effects and safety. Severe side effects
have been reported, such as medullary aplasia and necrosis of
the subcutaneous tissue at the injection site, following the admin-
istration of intravenous mitomycin-C at a total dose greater than
50 mg (9, 10). There have been reports of complications and a
compromised airway (e.g., partial or total airway obstruction) re-
lated to the use of mitomycin-C for the treatment of glottis and
subglottic stenosis (11).
Tension is one of the chief factors that determine the degree
of scar formation. Excessive tension on tissues has to be avoid-
ed in wound management because it compromises blood flow
and increases the fibroplastic response. Various surgical techniques,
such as placing scars in line with the relaxed skin tension lines,
using local flaps or undermining the wound edges, have been ap-
plied to reduce excessive tension of an incision (12). A new me-
thod to minimize the underlying muscle contracture would be a
desirable therapeutic modality for the healing of cutaneous wounds.
Botulinum toxin type A (Botox
�, Allergan, Irvine, CA, USA)
is known to be a potent neurotoxin that produces flaccid paral-
ysis of the striated muscle for a period of 2 to 6 months; it has
been safely used in humans in the clinical field for more than 20
yr. Its application to the ENT field provides a useful tool to treat
spasmodic dysphonia, autonomic dysfunction, Frey syndrome,
hemifacial spasm or synkinesis, and hyperfunctional lines (13,
14). Gassner and Sherris (15) reported that the chemoimmobi-
lization of facial wounds with Botox improved the cosmetic ap-
pearance. So, we hypothesized that a Botox-induced paralysis
of the musculature subjacent to the surgical wound with a skin
defect would minimize the repetitive tensile forces on the wound
edges, and this would result in a decreased fibroplastic response
and fibrosis of the wound (Fig. 1). This study was designed to in-
vestigate the antifibroblastic effect of Botox on wound healing in
a rat surgical wound model.
MATERIALS AND METHODS
Surgical wounds of the experimental animal
Fifteen male Wistar rats aged 120 to 150 days with weights that
ranged from 350-410 g were used. They were anesthetized by
consecutive intraperitoneal injections of Rumpune
� (20 mg/kg,
Bayer Korea, Seoul, Korea) and Ketamine
� (100 mg/kg, Yuhan
Company, Seoul, Korea). The animal care, housing and surgery
followed the guidelines of the Animal Experiment Committee,
Pusan National University Hospital. After each rat was shaved
and two identical circular areas were prepared on the dorsum of
each rat, and the distance between the areas was approximately
4 cm. The skin and subcutaneous tissue were then excised, but
the deep muscle was preserved at the base of the defect. The di-
ameter of the wound was 1.2 cm (Fig. 2). One of the wounds was
selected at random and it was treated with Botox. Botox (10 U,
0.5 mL) was injected into the deep musculature subjacent to the
wound immediately after the surgery. As a control, normal saline
(0.5 mL) was injected into the other wound.
Assessment of wound size
Visual assessment of the state of the wound healing was done
weekly by two otolaryngologists. They measured the lengths of
the major axis and the minor axis of the wound every week with
a ruler. The measurement of the area of the wound was calculat-
ed by the formula for an ellipse ([0.5× the length of the major
axis] [0.5× the length of the minor axis] [π ]) (16).
Histological assessment of wound healing 
After surgery, 5 rats were sacrificed at the 2nd week, 5 rats at
the 4th week and 5 rats at the 8th week. The skin wounds were
harvested, including the epidermis, dermis and subcutaneous loose
tissue with the surrounding normal tissue. The removed tissues
were fixed in formalin, processed and then embedded in paraf-
fin. The paraffin blocks were cut into 4-6 μ m thick slices and the
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Fig. 1. Methods for decreasing fibrosis and scar formation. We hypoth-
esized that the paralysis of the muscle(s) subjacent to a surgical wound
by Botox would decrease the fibrosis and scar formation.
Surgical techniques
(local flaps, undermining wound edge)
Decrease of tension Decrease of fibroblast
Chemical agents
(Mytomicin-C, 5-fluorouracil, Triamcinolone)
?
Paralysis of muscle subjacent to surgical wound
by botulinum toxin type A (author’s hypothesis)
Decreased
fibrosis and scar
Fig. 2. Dorsum of a rat showing the distinct surgical wounds. The sur-
gical wound (right) is injected with Botox.22 Clinical and Experimental Otorhinolaryngology  Vol. 2, No. 1: 20-27, March 2009
slices were stained with hematoxylin-eosin for histologic exami-
nation. To evaluate the degree of inflammation in both groups,
the number of inflammatory cells, including the neutrophils, plas-
ma cells and lymphocytes, was counted by a pathologist on high-
power fields (×400) three times. The analysis of the degree of
fibrosis was assessed by counting all the fibroblasts in 10 random-
ly selected high-power fields (×400). To evaluate the blood ves-
sel proliferation, we counted the number of blood vessels on the
high power field (×400), three times and we compared the mean
number of blood vessels in each group. The thickness of the heal-
ing wound was determined by measuring the length from the basal
layer of the epidermis to the deepest point of inflammation of the
fibrosis under microscopic examination. We used Masson-Tric-
hrome staining to evaluate the amount and density of the colla-
gen. We scored the staining intensity as grade 1: the same or slight-
ly decreased staining intensity compared with the surrounding
normal tissue, grade 2: moderately decreased staining intensity
compared with the surrounding normal tissue, and grade 3: mar-
kedly decreased staining intensity compared with the surround-
ing normal tissue.
Immunohistochemical analysis was performed on the forma-
lin-fixed, paraffin-embedded materials by using a primary anti-
body for TGF-β 1 (diluted 1:30) (Santa Cruz Biotechnology Inc,
CA, USA). Briefly, the sections were deparaffinized in xylene,
rehydrated, washed in distilled water, immersed in 10 mM cit-
rate buffer (pH 6) and then microwaved for 10 min. The sections
were treated with a 3% H2O2 solution to reduce the endogenous
peroxidase activity, and then they were washed in phosphate
buffered saline; they were subsequently subjected to incubation
with the primary antibody. Detection of the immunoreactive stain-
ing was obtained by the streptavidin biotin method with using
an LSAB kit (DAKO, Carpinteria, CA, USA). The sections were
subjected to a color reaction with diaminobenzidine and they were
counterstained with Mayer’s hematoxylin. TGF-β 1 showed cyto-
plasmic staining as a brown color. The degree of the expression
of the TGF-β 1 in both wounds was assessed by counting the fi-
broblasts that showed a brown color in 10 randomly selected
high-power fields (×400).
Statistical analysis
The Wilcoxon signed rank test was used to evaluate the differ-
ence of wound size between the Botox and control groups. The
Mann-Whitney test was used to assess the differences of inflam-
mation, fibroblasts, vessel proliferation, thickness of the wounds
and the expression of TGF-β 1 in the Botox and control wounds
at the 2nd, 4th, and 8th week. McNemar’s test was used to eval-
uate the difference of collagen maturation. All the P-values pre-
sented were two-sided, and the significance level was set at P<
0.05.
Fig. 3. Assessment of the surgical wounds. There are differences of
the wound size between the control (the left wound on each photograph)
and the Botox (the right wound on each photography) wounds at the
2nd (A), 4th (B), and 8th (C) week.
A B
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RESULTS
Assessment of the wound size
All the wounds were covered with the scab within the first day
following the surgical procedure. The Botox and control wounds
showed a progressive decrease in the size of the wound scab. Th-
ere was no significant difference between the two groups for the
formation and disappearance of the scabs. There were significant
differences of wound size at the 3th (47.1±10.5 mm
2 vs. 26.5
±11.5 mm
2, respectively) and 4th week (39.5±8.7 mm
2 vs.
20.2±9.2 mm
2, respectively) between the Botox and control
groups (P<0.05) (Fig. 3, 4). At the 8th week after surgery, all the
surgical wounds had the same appearance except for the size of
the scars.
Histological assessment of wound healing 
The Botox group (11.3±3.8, inflammatory cell number/high po-
wer field) showed less infiltration of inflammatory cells (11.3±
3.8, inflammatory cell number/high power field) than that of the
control group (25.0±8.8, inflammatory cell number/high power
field) at the 2nd week after surgery (P<0.05) (Table 1, Fig. 5).
A B C
D E F
Fig. 5. The histological findings of inflammatory cell infiltration. The Botox group shows less inflammatory cells than that of the control group at
the 2nd week after surgery. (A, C, E) control wound at the 2nd, 4th, and 8th week after surgery, respectively; (B, D, F) Botox wound at the 2nd,
4th, and 8th week after surgery, respectively (H&E, ×400).
Fig. 4. The change of wound size during the healing period. There are
significant differences of wound size between the Botox and control
wounds at the 3th and 4th week (*P<0.05).
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Table 1. The differences of the surgical wounds between the Botox
and control groups
HPF: high power field; TGF: transforming growth factor.
Inflammatory cells 2nd 25.0±8.8 11.3±3.8 0.048
(No./HPF) 4th 3.3±1.9 4.3±2.9 0.796
8th 0 0
Fibroblast 2nd 103.0±19.7 106.0±14.4 0.561
(No./HPF) 4th 68.6±7.0 49.8±6.6 0.016
8th 37.3±5.1 32.5±6.2 0.248
Vessel proliferation 2nd 6.0±0.8 6.5±1.2 0.536
(No./HPF) 4th 3.2±1.3 3.0±1.5 0.832
8th 2.5±0.6 2.3±1.3 0.730
Thickness of the 2nd 0.8±0.3 0.8±0.4 0.943
wound (mm) 4th 0.7±0.1 1.0±0.3 0.101
8th 1.1±0.1 1.2±0.1 0.534
Expression of 2nd 113.2±23.2 109.1±18.2 0.624
TGF-β 1 (No./HPF) 4th 70.2±8.3 45.2±4.2 0.012
8th 54.3±8.5 49.3±8.9 0.31224 Clinical and Experimental Otorhinolaryngology  Vol. 2, No. 1: 20-27, March 2009
However, there was no significant difference between the Botox
and control groups for the degree of the infiltration of inflamma-
tory cells at the 4th and 8th week after surgery.
The Botox group showed a lesser number of fibroblast and less
fibrosis (49.8±6.6, number of fibroblasts/high power field) than
that of the control group (68.6±7.0, number of fibroblasts/high
power field) at the 4th week after surgery (P<0.05) (Table 1, Fig.
6). However, there was no significant difference between the Bo-
A B C
D E F
Fig. 6. The histological findings for fibroblasts. The Botox group (D) shows less fibrosis than that of the control group (C) at the 4th week after
surgery. (A, C, E) the control wound at the 2nd, 4th, and 8th week after surgery, respectively; (B, D, F) the Botox wound at the 2nd, 4th, and 8th
week after surgery, respectively (H&E, ×400).
A B C
D E F
Fig. 7. Histological findings for the collagen density. The Botox group shows a much greater amount of collagen than that of the control group
at the 8th week after surgery. (A, C, E) control wound at the 2nd, 4th, and 8th week after surgery, respectively; (B, D, F) Botox wound at the 2nd,
4th, and 8th week after surgery, respectively (Masson-Trichrome, ×400).Lee B-J et al.: Effect of Botulinum Toxin Type A on Surgical Wounds  25
tox and control groups for the degree of fibrosis at the 2nd and
8th week after surgery (Table 1, Fig. 6).
There was no significant difference between the Botox and con-
trol groups for the degree of blood vessel proliferation, the thick-
ness of the inflammatory lesion and the fibrosis at the 2nd, 4th,
and 8th week after surgery (Table 1).
On the Masson-Trichrome stain for assessing the difference of
the amount and density of collagen, there was no significant dif-
ference between the Botox and control groups for the amount
of collagen and its density at the 2nd and 4th week after surgery.
The Botox group showed a much stronger collagen density than
that of the control group at the 8th week after surgery (P<0.05)
(Table 2, Fig. 7).
On the immunohistochemical staining, there was a lower expres-
sion of transforming TGF-β 1 in the Botox group (45.2±4.2, the
number cells with a positive TGF-β 1 expression/high power field)
than that of the control group (70.2±8.3, the number of cells with
a positive TGF-β 1 expression/high power field) at the 4th week
after surgery (Table 1, Fig. 8). However, there was no significant
difference between the Botox and control groups for the expres-
sion of TGF-β 1 at the 2nd and 8th week after surgery (Table 1).
DISCUSSION
Under normal conditions, the phases of wound healing are divid-
ed into three specific phases. The inflammatory phase is an attempt
to limit the tissue damage by stopping the bleeding, sealing the
surface of the wound and removing any necrotic tissue, foreign
bodies or bacteria that are present. Inflammatory cells regulate
the repair of the connective tissue matrix by the actions of vari-
ous secreted cytokines. The proliferative phase is the repair pro-
cesses of angiogenesis, fibroplasia and epithelization. This phase
is characterized by the formation of granulation tissue, and this
consists of a capillary bed, fibroblasts, macrophages and a loose
arrangement of collagen, fibronectin, hyaluronic acid and bacteria.
The maturation phase is the period of scar contracture with col-
lagen cross-linking, shrinking and a loss of edema. At this phase,
the acute and chronic inflammatory cells gradually diminish in
number, angiogenesis ceases and fibroplasia ends. The equilibri-
um between collagen synthesis and collagen degradation is grad-
ually restored. Although the three phases are described as a seq-
uence of events, these phases may occur simultaneously, and the
A B C
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Fig. 8. Immunohistochemical stain for TGF-β 1. The Botox group shows less of an expression of TGF-β 1 than that of the control group at the 4th
week after surgery. (A, C, E) control wound at the 2nd, 4th, and 8th week after surgery, respectively; (B, D, F) Botox wound at the 2nd, 4th, and
8th week after surgery, respectively (Immunohistochemical stain, ×400).
Stain intensity
Week Group P-value
Grade 1 Grade 2 Grade 3
Table 2. The degree of staining for the amount and density of colla-
gen in the surgical wounds between the Botox and control groups
(N=cases)
2nd Control 0 0 5 NA
Botox 0 0 5
4th Control 0 5 0 NA
Botox 0 5 0
8th Control 0 5 0 0.008
Botox 4 1 0phases with their individual processes may overlap (17).
Tension is one of the important factors that determine the de-
gree of fibrosis and scar formation. The relaxed skin tension lines
reflect the tension created by underlying muscular contracture.
Placement of scars in these lines or parallel to these lines will mini-
mize the propensity to form hypertrophic scars. However, scars
oriented against the relaxed skin tension lines are subject to repeti-
tive tension and this causes scar hypertrophy.
Immobilization is a basic therapeutic principle for wound heal-
ing. Repeated microtrauma that’s caused by continuous displace-
ment of the healing tissue of the wound induces a prolonged and
strong inflammatory response and an increased metabolic activ-
ity during the healing process. As a consequence, the extracel-
lular deposition of collagen and glycosaminoglycans can intensi-
fy and lead to a hypertrophic scar. 
Botulinum toxin type A acts at the neuromuscular junction by
blocking vesicle transport of acetylcholine, and in essence, this
produces a chemical denervation (13, 14). It has been used safe-
ly and effectively to control the symptoms of patients with dis-
orders of a neural origin and voice disorders. In this study, it was
observed that most surgical wounds injected with Botox had a
larger size when compared with the control wound until the 8th
week. There was a significant difference between the Botox and
control groups for the wound size at the 3th and 4th week (P<
0.05). The reason for the difference of wound size is presumed
to be the decreased wound contracture power of the underlying
muscle tension by Botox. Although there are possibilities that
Botox has a direct effect on the inflammatory cells or it inhibits
the mediators by a direct mechanism, we could not find any pre-
vious study that reported on these action mechanisms.
The wounds of the Botox group showed less infiltration of in-
flammatory cells than that of the control group at the 2nd week
after surgery (P<0.05). However, there was no significant differ-
ence between the Botox and control groups for the degree of the
infiltration of inflammatory cells at the 4th and 8th week after
surgery. The reason for the difference of the inflammatory res-
ponse at the 2nd week is presumed to be the decrease of micro-
trauma by the immobilization of the underlying muscle injected
with Botox (Fig. 5).
For the histological findings on the H&E stain, the surgical wo-
unds of the Botox group showed a significantly smaller number
of fibroblasts and less fibrosis than the control wounds at the 4th
week after surgery (P<0.05). The reason for the difference of the
number of fibroblasts and the degree of fibrosis is presumed to
be the decreased release of several cytokines, such as platelet-de-
rived growth factor, TGF, epidermal growth factor, fibroblast gro-
wth factor and insulin-like growth factor, by the decreased inflam-
matory response and the short period of inflammation. This result
suggests that Botox may be used to decrease the fibrosis during
the healing process of surgical wounds by decreasing the under-
lying muscle tension (Fig. 9). However, there was no significant
difference between the Botox and control groups for the thick-
ness of the healing wound at the 2nd, 4th, and 8th week after
surgery.
For the histological findings of Masson-Trichrome staining, the
wounds of the Botox group showed a much greater amount of
collagen than that of the collagen group at the 8th week after sur-
gery. The collagen maturation in the Botox group was increased
and the maturation was faster than that of the control group at
the 8th week. The reason for the difference of the degree of col-
lagen maturation is thought to be associated with the increased
collagen maturation by the decreased inflammation response and
the shortened period of the inflammatory phase for the surgical
wounds of the Botox group (Fig. 9).
On the immunohistochemical staining, the wounds of the Botox
group showed a lower expression of TGF-β 1 than that of the con-
trol group at the 4th week after surgery. TGF-βis one of major
important cytokines in the wound healing process. This cytokine
is produced by a host of cells, including platelets, fibroblasts, sm-
ooth muscle cells, endothelial cells, keratinocytes, lymphocytes
and macrophages (17). It increases collagen synthesis and stim-
ulates keratinocyte migration, angiogenesis and fibroplasias (17).
TGF-β 1 is the most abundant isoform of TGF-β . The reason for
the difference of the expression of TGF-β 1 is the decreased inflam-
mation response at the surgical wounds of the Botox group (Fig. 8).
For the surgical wound treated with mitomycin-C in a previous
study, the histological analysis at the 1st month after treatment
revealed a significant reduction in fibrosis of the wounds compared
with the untreated wounds. After the third month, the degree of
fibrosis was comparable between the surgical wounds treated with
mitomycin-C and the surgical wounds that were not treated with
mitomycin-C (18). In our study, although there was no significant
difference between the Botox and control wounds for the num-
ber of fibroblasts at the 8th week after surgery, the wounds treat-
ed with Botox showed a smaller number of fibroblast and less
fibrosis than did the control wounds at the 4th week after surgery.
These results demonstrated that the antifibroblastic effect of Bo-
tox in surgical wounds was similar to that of mitomycin-C. There-
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Fig. 9. Our proposed mechanism for the effect of Botox on wound he-
aling.
Decreased wound contracture
Botox
� injection
Decreased microtrauma
Decreased inflammation response Decrease of fibroblast
Increased collagen maturation
Decreased various cytokines release,
including TGF-β 1
Decrease of tension Increase of wound sizefore, Botox can be used for the treatment and to prevent stenosis
of tubular structures, such as the larynx, trachea and nasal cavi-
ty, the same as mitomycin-C. Further studies are needed that will
focus on the relationship between the degree and the effective
period of decreased fibrosis and the dose of Botox, and these stud-
ies will have to use an appropriate, large animal experimental mo-
del of airway injury.
Gassner et al. (19) have reported that an injection of Botox into
the musculature underlying cutaneous wounds resulted in immo-
bilization of the healing wounds and a significantly better cosmet-
ic appearance than was seen for the nonimmobilized control wo-
unds in primates. In the blinded, prospective and randomized
clinical trial for forehead wounds, Gassner et al. (20) have also
reported that botulinum toxin-induced immobilization of wounds
enhances healing and they suggested its use in selected patients
to improve the eventual appearance of the scar. Khera et al. (21)
have reported the efficacy of Botox for preventing recurrence of
uretheral stricture. The results of these above-mentioned studies
are consistent with our results.
Wounds treated with mitomycin-C show delayed scab healing.
It is suspected that mitomycin-C inhibits fibroblast proliferation
and it might reduce the epithelial proliferation and healing. Yet
in this current study, although Botox was shown to decrease the
fibrosis in the healing process of surgical wounds, there was no
significant difference between the Botox and control groups’ sur-
gical wounds at the period of the disappearance of scab. Although
both the Botox and control surgical wounds were initially the same
size, the surgical wounds treated with Botox became larger than
the control wounds according to the decreased wound contrac-
ture and the reduced number of fibroblasts during the wound heal-
ing phase. These results suggest that Botox can be used to decrease
the fibrosis and inhibit fibroblast proliferation without damaging
the epithelial growth during the healing process of surgical wounds.
The Botox-treated group showed a larger wound size, less infil-
tration of inflammatory cells and less fibrosis, a much greater am-
ount of collagen and a lower expression of TGF-β 1 than that of
the control group. Botox might be used, instead of mitomycin-C,
to decrease the fibrosis of surgical wound without damaging the
epithelial growth in situations for which decreased fibrosis is nec-
essary, such as for treating laryngeal, tracheal and nasal stenosis.
Further studies are needed that will determine the effective, safe
doses of Botox injection and whether topical application of Botox
cream might be as effective as injections of Botox. The expres-
sions of the genes involved in wound healing in an appropriate
laryngeal stenosis animal model should also be studied.
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